Quinazolines for PDK1 inhibition

US7932262B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Savithri Ramurthy · Walnut Creek, US
• Xiaodong Lin · Walnut Creek, US
• Sharadha Subramanian · San Ramon, US
• Alice Rico · Castro Valley, US
• Xiaojong M. Wang · Livermore, US
• Rama Jain · Danville, US
• Jeremy M. Murray · South San Francisco, US
• Stephen E. Basham · Oakland, US
• Robert L. Warne · San Francisco, US
• Wei Shu · Danville, US
• Yasheen Zhou · Moraga, US
• Jeffrey H. Dove · Castro Valley, US
• Mina E. Aikawa · Alameda, US
• Payman Amiri · Emeryville, US
• Weibo Wang · Moraga, US
• Johanna Jansen · San Francisco, US
• Allan S. Wagman · Belmont, US
• Keith B. Pfister · Emeryville, US
• Simon Ng · Walnut Creek, US

Key dates

• Filing date: Apr 5, 2007
• Grant date: Apr 26, 2011
• Expiry date: Apr 5, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.